Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer
Clinical trial NCT05088967 · TERMINATED
Trial details
- NCT number
- NCT05088967
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-02
- Primary completion
- 2021-12-31
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.